Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review

• Main Authors: Austin Nguyen, Sheila Bhavsar, Erinn Riley, Gabriel Caponetti, Devendra Agrawal
• Format: Article
• Language: English
• Published: Thieme Revinter Publicações Ltda. 2016-04-01
• Series: International Archives of Otorhinolaryngology
• Subjects: hmgb1 protein; advanced glycosylation end product-specific receptor; head and neck neoplasms
• Online Access: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0036-1583168
• ISSN: 1809-9777; 1809-4864

Abstract Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.